英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

sestet    
n. 六重唱曲,十四行诗

六重唱曲,十四行诗

sestet
n 1: the cardinal number that is the sum of five and one [synonym:
{six}, {6}, {VI}, {sixer}, {sise}, {Captain Hicks}, {half a
dozen}, {sextet}, {sestet}, {sextuplet}, {hexad}]
2: six performers or singers who perform together [synonym:
{sextet}, {sextette}, {sestet}]
3: a set of six similar things considered as a unit [synonym:
{sextet}, {sextette}, {sestet}]
4: a musical composition written for six performers [synonym:
{sextet}, {sextette}, {sestet}]
5: a rhythmic group of six lines of verse


请选择你想看的字典辞典：
单词字典翻译
Sestet查看　Sestet　在百度字典中的解释百度英翻中〔查看〕
Sestet查看　Sestet　在Google字典中的解释Google英翻中〔查看〕
Sestet查看　Sestet　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • SARCLISA® (isatuximab-irfc) | About Multiple Myeloma
    Multiple myeloma cells and M-proteins can cause damage to the bones in which they are located They can also travel into the blood and harm the body; What is SARCLISA? SARCLISA is a prescription medicine used in combination with: The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies
  • Press Release: Sarclisa approved in the US as the first anti . . . - Sanofi
    Advancing Sarclisa in multiple myeloma Sanofi continues to advance Sarclisa as part of a patient-centric clinical development program, which includes several phase 2 and phase 3 studies across the MM treatment continuum spanning six potential indications In addition, the company is evaluating a subcutaneous administration method for Sarclisa
  • ASCO: Sarclisa is first anti-CD38 to significantly improve . . . - Sanofi
    “The significant progression-free survival benefit observed with Sarclisa combination therapy compared to VRd is important and encouraging for patients with newly diagnosed multiple myeloma Effective frontline therapy has the potential to modify the course of the disease, which is a key outcome for transplant-ineligible patients who often
  • European CHMP Recommends Sarclisa (isatuximab) for TE NDMM | Intl . . .
    European CHMP Recommends Sarclisa (isatuximab-irfc) for Approval to Treat Transplant-Eligible Newly Diagnosed Multiple Myeloma June 23, 2025—According to a press release from Sanofi, "The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Sarclisa® in combination with bortezomib, lenalidomide, and
  • SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma
    The CHMP has now recommended approval of Sarclisa in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple
  • FDA approves isatuximab-irfc for multiple myeloma | FDA
    On March 31, 2021, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, sanofi-aventis U S LLC) in combination with carfilzomib and dexamethasone, for the treatment of adult
  • Darzalex Faspro, Sarclisa Approvals for Multiple Myeloma
    For people newly diagnosed with multiple myeloma, stem cell transplants are a standard treatment and can lead to long-term remission However, because of the intense chemotherapy-based conditioning regimen required to receive a stem cell transplant, some people—including those with other health conditions or pre-existing heart or lung issues
  • Sarclisa (isatuximab-irfc) for multiple myeloma
    How does Sarclisa work? Multiple myeloma is a rare blood cancer in which plasma cells, a type of immune cell, grow uncontrollably in the bone marrow, where blood cells are formed Instead of producing antibodies that help the body fight infections and other threats, cancerous plasma cells, or myeloma cells, produce an abnormal antibody called M
  • Sanofis Sarclisa gets one up on rival Darzalex in myeloma
    The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen alongside bortezomib, lenalidomide, and dexamethasone (VRd), for
  • Sanofi moves on J J in first-line myeloma with FDA nod
    ASCO: With first-in-class win, Sanofi's Sarclisa looks to step out of J J's multiple myeloma shadow Challenging Darzalex won’t be easy Worldwide sales of the J J med jumped 22% and reached $9 7





中文字典-英文字典  2005-2009